Table 2. Correlations between clinical features and miR-520g expression in 116 ovarian cancer patients.
| Characteristics | No. of patients (%) | miR-520g expression | P * | |
|---|---|---|---|---|
| Low n = 40 (%) | High n = 76 (%) | |||
| Age | ||||
| < 50 | 43 (37.1) | 14 (35.0) | 29 (38.2) | .738 |
| ≥ 50 | 73 (62.9) | 26 (65.0) | 47 (61.8) | |
| Ascites | ||||
| < 100 | 41 (35.3) | 20 (50.0) | 21 (27.6) | 0.017 |
| ≥ 100 | 75 (64.7) | 20 (50.0) | 55 (72.4) | |
| Serum CA-125 level | ||||
| < 35 | 8 (7.0) | 3 (7.5) | 5 (6.6) | 0.852 |
| ≥ 35 | 108 (93.0) | 37 (92.5) | 31 (93.4) | |
| Lymph node metastasis | ||||
| Negative | 71 (61.2) | 35 (82.6) | 36 (0.0) | < 0.001 |
| Positive | 45 (38.8) | 5 (17.4) | 40 (100.0) | |
| Differentiation | ||||
| G1 | 23 (19.8) | 12 (30.0) | 11 (14.5) | 0.002 |
| G2 | 41 (35.4) | 19 (47.5) | 22 (28.9) | |
| G3 | 52 (44.8) | 9 (22.5) | 43 (56.6) | |
| Histology type | ||||
| Serous | 82 (70.7) | 28 (70.0) | 54 (71.1) | 0.114 |
| Mucinous | 14 (12.1) | 8 (20.0) | 6 (7.9) | |
| Endometrioid | 16 (13.8) | 4 (10.0) | 12 (15.8) | |
| Clear cell | 4 (3.4) | 0 (0.00) | 4 (5.3) | |
| Residual tumor size | ||||
| < 1 cm | 80 (69.0) | 37 (92.5) | 43 (56.6) | < 0.001 |
| ≥ 1 cm | 36 (31.0) | 3 (7.5) | 33 (43.4) | |
| FIGO stage | ||||
| I–II | 15 (12.9) | 12 (30.0) | 3 (3.9) | < 0.001 |
| III–IV | 101 (87.1) | 28 (70.0) | 73 (96.1) | |
| Chemotherapy plan | ||||
| TP | 73 (62.9) | 18 (45.0) | 55 (72.3) | 0.004 |
| PAC | 43 (37.1) | 22 (55.0) | 21 (27.7) | |
| Chemoresistance | ||||
| Yes | 30 (25.9) | 2 (5.0) | 28 (32.6) | < 0.001 |
| No | 86 (74.1) | 38 (95.0) | 48 (67.4) | |
*
p < 0.05 indicates a significant relationship among the variables.
FIGO: International Federation of Gynecology and Obstetrics.
TP: cisplatin and paclitaxel, PAC: cisplatin, epirubicin, and cyclophosphamide.